Skip to main content
main-content

Hematologic cancers

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Scientific summary

Diffuse large B-cell lymphoma management: Exploring novel treatment strategies

Diffuse large B-cell lymphoma management: Exploring novel treatment strategies

This program was made possible thanks to independent educational sponsorship from MorphoSys.

medwireNews editor's pick

‘Reassuring’ childbirth rate reported for Hodgkin lymphoma survivors

Newborn baby

The birth rate for women who are relapse-free after treatment for Hodgkin lymphoma has risen in recent years, becoming comparable with that of the general population regardless of disease stage or treatment.

medwireNews editor's pick

Liposomal cytarabine–daunorubicin prolongs high-risk secondary AML survival

IV drip 2

Phase III trial findings support the use of a liposome-encapsulated formulation of cytarabine and daunorubicin in older patients with a new diagnosis of high-risk secondary acute myeloid leukemia.

medwireNews@ASCO2018

Hematologic cancers coverage at ASCO Annual Meeting 2018

ASCO 2018
Expert opinion

Discontinuing tyrosine kinase inhibitors in chronic myeloid leukemia

Ehab Atallah

Tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) can result in prolonged and deep responses in many patients. In such cases, can TKIs be safely discontinued to avoid adverse side effects and costs? Etab Atallah (Medical College of Wisconsin, USA) discusses the current issues surrounding TKI discontinuation in CML.

10-12-2018 | B-cell lymphoma | News

Long-term data further support axicabtagene ciloleucel use for refractory large B-cell lymphoma

The 2-year follow-up results from the phase I/II ZUMA-1 trial of patients with refractory large B-cell lymphoma show that the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel remains efficacious and manageable in the long term.

07-12-2018 | Chronic lymphocytic leukemia | News

Ibrutinib plus obinutuzumab more effective than chemoimmunotherapy in CLL

Combining ibrutinib rather than chlorambucil with obinutuzumab significantly improves progression-free survival in previously untreated patients with chronic lymphocytic leukemia, phase III study data show.

05-12-2018 | Diffuse large B-cell lymphoma | News

Durable response to tisagenlecleucel shown in DLBCL

Heavily pretreated adults with relapsed or refractory diffuse large B-cell lymphoma respond well to treatment with the chimeric antigen receptor T-cell therapy tisagenlecleucel, show results of the pivotal JULIET trial.

Case reports and studies

09-03-2017 | Lymphoma | Case report | Article

Cutaneous T-cell lymphoma

In this case report, an 83-year-old female presented to the physician with a progressing pruritic cutaneous rash that started 8 years ago. Read this review to understand how her condition was managed.

In: Management of Lymphomas: A Case-Based Approach. Edited by Zain J & Kwak LW. Springer International Publishing, 2017. doi:10.1007/978-3-319-26827-9_10

09-03-2017 | Lymphoma | Case report | Article

CNS lymphoma

This  case report describes the presentation, workup and staging, and treatment recommendations for a 56-year-old woman who presented with vertigo, headaches, and frequent falls.

In: Management of Lymphomas: A Case-Based Approach. Edited by Zain J & Kwak LW. Springer International Publishing, 2017. doi:10.1007/978-3-319-26827-9_14

14-03-2017 | Lymphoma | Case report | Article

SLL and CLL

A 72-year-old man with a history of diabetes mellitus, hypertension, and hypercholesterolemia self-palpated a left submandibular lump – read how the City of Hope team approached his case.

In: Management of Lymphomas: A Case-Based Approach. Edited by Zain J & Kwak LW. Springer International Publishing, 2017. doi:10.1007/978-3-319-26827-9_4

Journal articles and book chapters

06-08-2018 | Guidelines | Article

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy

Mahadeo KM et al. Nat Rev Clin Oncol 2018. doi:10.1038/s41571-018-0075-2.

05-06-2018 | Radiotherapy | Article

Safety of combining radiotherapy with immune-checkpoint inhibition

Hwang WL et al. Nat Rev Clin Oncol 2018. doi: 10.1038/s41571-018-0046-7

31-05-2018 | B-cell lymphoma | Article

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

Dimopoulos MA et al. N Engl J Med 2018; 378(25): 2399-2410. doi:10.1056/NEJMoa1802917

20-03-2018 | Multiple myeloma | Article

Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review

Sparano F et al. Support Care Cancer 2018; 26: 2075. doi:10.1007/s00520-018-4137-x

03-03-2018 | Hematologic cancers | Article

Sexual health in patients with hematological malignancies: a neglected issue

Niscola P et al. Support Care Cancer 2018; 26(6): 1699-1701. doi:10.1007/s00520-018-4124-2.

27-02-2018 | Acute leukemia | Article

Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis

Maruffi M et al. Leukemia 2018. doi:10.1038/s41375-018-0058-4

image credits